Analyst Consensus ?
ConsensusBuy52 ratings
Bullish4280.8%
Neutral815.4%
Bearish23.8%
DexCom, Inc. · DXCM · FY2026 Q1 · Calendar Q2 2026
Dexcom Beats Q1 Estimates as G7 15-Day Sensor Drives Record Patient Starts
Dexcom reported a strong Q1 FY2026 with revenue of $1.19B (up 15% YoY, 12% organic) and EPS of $0.56, both beating consensus. The G7 15-day CGM launch is driving record new-patient starts, conversions, and gross margin expansion. Management reaffirmed full-year revenue guidance of $5.16-$5.20B and raised operating and EBITDA margin targets, while disclosing a 50-100 bps inflation headwind from oil and resin costs. Key catalysts ahead include potential CMS coverage for type-2 non-insulin patients, the international Stello launch, and an Investor Day. The stock gained 2.75% on the report and has since drifted +22%, with the analyst consensus target at $84.18 versus the current price of $73.81.
Reported After market closeNASDAQHealthcare
$28.99B market cap
100quality score
Company context
Snapshot as of publicationDexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional…
Earnings scorecard
Reported versus consensus
Reported EPS
$0.56
Consensus $0
EPS surprise
+20.3%
Reported versus consensus
Reported revenue
$1.19B
Consensus $1.17B
Revenue surprise
+1.5%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$73.61Current
$28.12Low
$75.98Average
$146High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Buy | Buy | Maintain | Jul 16, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 15, 2026 |
| Deutsche Bank | Buy | Buy | Maintain | Jun 23, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jun 15, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jun 10, 2026 |
| Stifel | Buy | Buy | Maintain | Jun 5, 2026 |
| Citigroup | Buy | Buy | Maintain | May 28, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | May 18, 2026 |
| Barclays | Underweight | Underweight | Maintain | May 18, 2026 |
| B of A Securities | Buy | Buy | Maintain | May 18, 2026 |
| BTIG | Buy | Buy | Maintain | Mar 9, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 13, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Jan 9, 2026 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Dec 2, 2025 |
| Argus Research | Buy | Buy | Maintain | Nov 7, 2025 |
| UBS | Buy | Buy | Maintain | Nov 3, 2025 |
| RBC Capital | Outperform | Outperform | Maintain | Oct 31, 2025 |
| JP Morgan | Neutral | Neutral | Maintain | Oct 31, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Oct 1, 2025 |
| Baird | Outperform | Outperform | Maintain | Sep 26, 2025 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Jul 31, 2025 |
| Oppenheimer | Outperform | Outperform | Maintain | Jul 31, 2025 |
| Redburn Atlantic | Buy | Neutral | Upgrade | Feb 3, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 25, 2024 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 10, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Apr 29, 2022 |
| Guggenheim | Buy | Neutral | Upgrade | Jan 7, 2022 |
| Stephens & Co. | Overweight | Overweight | Maintain | Mar 26, 2020 |
| CFRA | Hold | Hold | Maintain | Feb 14, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Nov 7, 2019 |
| Piper Jaffray | Overweight | Overweight | Maintain | Nov 7, 2019 |
| BMO Capital | Outperform | Outperform | Maintain | Sep 3, 2019 |
| Bank of America | Buy | Buy | Maintain | Aug 1, 2019 |
| Northland Securities | Market Perform | Underperform | Upgrade | Sep 12, 2018 |
| Northland Capital Markets | Market Perform | Underperform | Upgrade | Sep 12, 2018 |
| Berenberg | Buy | Hold | Upgrade | Aug 6, 2018 |
| Jefferies | Buy | Buy | Maintain | Aug 2, 2018 |
| B. Riley FBR | Buy | Neutral | Upgrade | May 5, 2018 |
| BTIG Research | Neutral | Buy | Downgrade | May 3, 2017 |
| B. Riley Securities | Buy | Neutral | Upgrade | Dec 15, 2016 |
| Desjardins | Buy | Hold | Upgrade | Sep 16, 2016 |
| Sterne Agee CRT | Buy | Neutral | Upgrade | Oct 15, 2015 |
| Sterne Agee | Buy | Neutral | Upgrade | Oct 15, 2015 |
| Leerink Swann | Outperform | Market Perform | Upgrade | Oct 15, 2015 |
| Feltl & Co. | Sell | Hold | Downgrade | Feb 20, 2014 |
| Wedbush | Outperform | Outperform | Maintain | Nov 7, 2013 |
| Benchmark | Buy | Buy | Maintain | Nov 7, 2013 |
| Wunderlich Securities | Hold | Buy | Downgrade | Jun 10, 2013 |
| Wunderlich | Hold | Buy | Downgrade | Jun 10, 2013 |
| PiperJaffray | Overweight | Overweight | Maintain | Sep 20, 2012 |
| McNicoll Lewis Vlak | Hold | Hold | Maintain | May 3, 2012 |
| Brean Capital | Buy | Buy | Maintain | Feb 24, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $73.61. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $96 | $73.37 | +30.4% | Jul 28, 2026 |
| Truist Financial | Analyst unavailable | $87 | $77.61 | +18.2% | Jul 16, 2026 |
| Deutsche Bank | Analyst unavailable | $86 | $69.07 | +16.8% | Jun 23, 2026 |
| Piper Sandler | Matt O'Brien | $88 | $75.37 | +19.5% | Jun 15, 2026 |
| UBS | Analyst unavailable | $95 | $78.42 | +29.1% | Jun 10, 2026 |
| Mizuho Securities | Anthony Petrone | $85 | $76.62 | +15.5% | Jun 9, 2026 |
| Raymond James | Analyst unavailable | $91 | $76.62 | +23.6% | Jun 8, 2026 |
| Stifel Nicolaus | Jonathan Block | $90 | $72.59 | +22.3% | Jun 5, 2026 |
| Canaccord Genuity | Analyst unavailable | $82 | $61.63 | +11.4% | May 18, 2026 |
| Barclays | Matt Miksic | $64 | $61.63 | -13.1% | May 18, 2026 |
| Bernstein | Analyst unavailable | $77 | $61.03 | +4.6% | May 1, 2026 |
| Robert W. Baird | Analyst unavailable | $80 | $61.82 | +8.7% | May 1, 2026 |
| Mizuho Securities | Anthony Petrone | $75 | $61.65 | +1.9% | May 1, 2026 |
| Raymond James | Analyst unavailable | $81 | $59.55 | +10.0% | May 1, 2026 |
| Canaccord Genuity | Analyst unavailable | $100 | $59.55 | +35.9% | May 1, 2026 |
| Barclays | Analyst unavailable | $67 | $59.55 | -9.0% | May 1, 2026 |
| Robert W. Baird | Analyst unavailable | $87 | $70.67 | +18.2% | Feb 13, 2026 |
| Mizuho Securities | Anthony Petrone | $90 | $65.08 | +22.3% | Feb 13, 2026 |
| Canaccord Genuity | Analyst unavailable | $95 | $65.08 | +29.1% | Feb 13, 2026 |
| Barclays | Analyst unavailable | $72 | $65.08 | -2.2% | Feb 13, 2026 |
| Barclays | Analyst unavailable | $71 | $69.67 | -3.5% | Jan 12, 2026 |
| Bernstein | Analyst unavailable | $86 | $68.43 | +16.8% | Jan 9, 2026 |
| Mizuho Securities | Analyst unavailable | $78 | $66.37 | +6.0% | Dec 17, 2025 |
| Leerink Partners | Mike Kratky | $92 | $65.38 | +25.0% | Dec 16, 2025 |
| Morgan Stanley | Patrick Wood | $75 | $63.52 | +1.9% | Dec 2, 2025 |
| Morgan Stanley | Analyst unavailable | $63 | $55.21 | -14.4% | Nov 10, 2025 |
| Bernstein | Lee Hambright | $84 | $58.22 | +14.1% | Nov 3, 2025 |
| Barclays | Analyst unavailable | $80 | $58.22 | +8.7% | Nov 3, 2025 |
| Piper Sandler | Matt O'Brien | $75 | $56.97 | +1.9% | Oct 31, 2025 |
| RBC Capital | Analyst unavailable | $85 | $56.95 | +15.5% | Oct 31, 2025 |
| Robert W. Baird | Analyst unavailable | $82 | $59.19 | +11.4% | Oct 31, 2025 |
| Wells Fargo | Analyst unavailable | $93 | $68.2 | +26.3% | Oct 31, 2025 |
| Canaccord Genuity | William Plovanic | $99 | $68.2 | +34.5% | Oct 31, 2025 |
| Piper Sandler | Matt O'Brien | $100 | $68.44 | +35.9% | Oct 21, 2025 |
| Truist Financial | Richard Newitter | $94 | $65.55 | +27.7% | Oct 15, 2025 |
| Robert W. Baird | Analyst unavailable | $90 | $68.3 | +22.3% | Sep 26, 2025 |
| RBC Capital | Shagun Singh | $120 | $68.62 | +63.0% | Oct 8, 2024 |
| Stifel Nicolaus | Mathew Blackman | $100 | $72.28 | +35.9% | Aug 22, 2024 |
| RBC Capital | Shagun Singh | $130 | $72.36 | +76.6% | Aug 16, 2024 |
| Barclays | Matt Miksic | $113 | $64 | +53.5% | Jul 29, 2024 |
| Oppenheimer | Steven Lichtman | $115 | $107.85 | +56.2% | Jul 26, 2024 |
| Piper Sandler | Matt O\'Brien | $90 | $63.22 | +22.3% | Jul 26, 2024 |
| Canaccord Genuity | William Plovanic | $89 | $107.85 | +20.9% | Jul 26, 2024 |
| RBC Capital | Shagun Singh | $72.5 | $31.77 | -1.5% | Jul 26, 2024 |
| Stifel Nicolaus | Mathew Blackman | $132 | $112.66 | +79.3% | Jul 12, 2024 |
| Oppenheimer | Steven Lichtman | $150 | $115.23 | +103.8% | Jun 3, 2024 |
| Redburn Partners | Issie Kirby | $130 | $127.64 | +76.6% | May 30, 2024 |
| RBC Capital | Shagun Singh | $165 | $134.48 | +124.2% | Mar 12, 2024 |
| Oppenheimer | Steven Lichtman | $122 | $88.91 | +65.7% | Oct 27, 2023 |
| Morgan Stanley | Analyst unavailable | $131 | $114.45 | +78.0% | Jan 6, 2023 |
| Stifel Nicolaus | Stifel Stifel | $130 | $111.44 | +76.6% | Dec 26, 2022 |
| Citigroup | Analyst unavailable | $146 | $116.64 | +98.3% | Dec 12, 2022 |
| Piper Sandler | Matt O'Brien | $120 | $95.21 | +63.0% | Oct 7, 2022 |
| Raymond James | Analyst unavailable | $101 | $82.08 | +37.2% | Aug 1, 2022 |
| Morgan Stanley | Analyst unavailable | $83 | $86.99 | +12.8% | Jul 29, 2022 |
| Piper Sandler | Matt O'Brien | $110 | $86.99 | +49.4% | Jul 28, 2022 |
| Bernstein | Lee Hambright | $105 | $76.5 | +42.6% | Jul 15, 2022 |
| BTIG | Marie Thibault | $105 | $76.6 | +42.6% | Jun 28, 2022 |
| Morgan Stanley | Analyst unavailable | $91 | $69.31 | +23.6% | Jun 15, 2022 |
| Morgan Stanley | Analyst unavailable | $90.75 | $70.74 | +23.3% | Jun 13, 2022 |
| Morgan Stanley | Analyst unavailable | $22.69 | $19.28 | -69.2% | Jun 7, 2022 |
| Leerink Partners | Danielle Antalffy | $31.25 | $24.79 | -57.5% | May 3, 2022 |
| Raymond James | Analyst unavailable | $30.38 | $26.05 | -58.7% | Apr 29, 2022 |
| Piper Sandler | Analyst unavailable | $30 | $25.83 | -59.2% | Apr 29, 2022 |
| BTIG | Marie Thibault | $35 | $31.02 | -52.5% | Apr 21, 2022 |
| Bank of America Securities | Travis Steed | $31.25 | $26.5 | -57.5% | Mar 3, 2022 |
| Citigroup | Joanna Wuensch | $39.38 | $26.28 | -46.5% | Feb 11, 2022 |
| Oppenheimer | Steven Lichtman | $36.25 | $26.9 | -50.8% | Jan 31, 2022 |
| Wells Fargo | Larry Biegelsen | $35.94 | $27.2 | -51.2% | Jan 19, 2022 |
| Raymond James | Jayson Bedford | $33.62 | $27.2 | -54.3% | Jan 19, 2022 |
| Canaccord Genuity | Kyle Rose | $39.06 | $38.95 | -46.9% | Oct 29, 2021 |
| Berenberg Bank | Ravi Misra | $39.38 | $38.95 | -46.5% | Oct 29, 2021 |
| UBS | Matthew Taylor | $41.25 | $38.95 | -44.0% | Oct 29, 2021 |
| Jefferies | Anthony Petrone | $40.94 | $38.95 | -44.4% | Oct 29, 2021 |
| Stephens | Chris Cooley | $34.12 | $32.22 | -53.6% | Jul 30, 2021 |
| J.P. Morgan | Robbie Marcus | $28.12 | $24.38 | -61.8% | Jun 9, 2021 |
Track every rating change on DXCM the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session close
Stock move
+3.0%
Event window
SPY move
+0.3%
Same window
Abnormal move
+2.7%
Stock minus SPY
Volume
2.5×
Versus trailing sessions
Subsequent drift
+22.0%
Up to 20 sessions
DXCMSPY benchmark
Follow DXCM with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Q1 revenue of $1.19B beat estimates by 1.5%; EPS of $0.56 beat by 20%. Record global new-patient start quarter driven by G7 15-day CGM adoption. Full-year revenue guidance reaffirmed at $5.16-$5.20B; operating and EBITDA margins raised. Prime Therapeutics will cover Dexcom CGM for all people with diabetes starting summer 2026. A 50-100 bps gross margin headwind from oil and resin price inflation was newly disclosed.
Guidance delta
Full-year FY2026 revenue guidance reaffirmed at $5.16-$5.20B, narrowing the prior $5.16-$5.25B range at the upper end. Non-GAAP operating and EBITDA margin targets were raised. A new 50-100 bps gross margin headwind from oil and resin inflation was disclosed. Guidance sentiment: maintained.
Key takeaways
- Q1 revenue grew 15% YoY (12% organic) to $1.19B, beating consensus by 1.5%; EPS of $0.56 beat by 20%
- Record global new-patient start quarter driven by G7 15-day CGM launch and adoption
- Prime Therapeutics coverage expands access to all people with diabetes starting summer 2026
- Full-year revenue guidance reaffirmed at $5.16-$5.20B; operating and EBITDA margin targets raised
- $2.4B cash position provides flexibility for buybacks, M&A, and capital projects
Management priorities
- Driving G7 15-day CGM adoption and conversion across U.S. and international markets
- Expanding access through payer wins and pursuing CMS coverage for type-2 non-insulin patients
- International expansion of Stello and a new CGM system to extend market reach
- Broader rollout of Smart Basal beyond pilot sites
- Investor Day to detail product pipeline, capital allocation, and long-term assumptions
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-30T14:32:15.004350+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T14:32:15.001836+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.